| NKCF | natural killer cytotoxic factor |
|---|---|
| NKSF | natural killer cell stimulatory factor |
| NKTR | natural killer triggering receptor |
| NS | natural science; Neosporin; nephrosclerosis; nephrotic syndrome; nervous system; neurological surger... |
| NTA | natural thymocytotoxic autoantibody; nitrilotriacetic acid; Nurse Training Act |
| lichen planus, oral | Oral lesions accompanying cutaneous lichen planus or often occurring alone. The buccal mucosa, lips, gingivae, floor of the mouth, and palate are usually affected (in a descending order of frequency). Typically, oral lesions consist of radiating white or gray, velvety, threadlike lines, arranged in a reticular pattern, at the intersection of which there may be minute, white, elevated dots or streaks (wickham's striae). (12 Dec 1998) |
|---|---|
| live oral poliovirus vaccine | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| acupuncture therapy | Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. Heat or moxibustion and acupressure may be used in conjunction. (12 Dec 1998) |
| adjuvant therapy | <oncology, pharmacology> Treatment that is added to increase the effectiveness of a primary treatment. In cancer, adjuvant treatment usually refers to chemotherapy, hormonal therapy or radiation therapy after surgery to increase the likelihood of killing all cancer cells. (14 May 1997) |
| alternative therapy | A term given to nonconventional therapy usually given by persons who do not have a medical qualification. (16 Dec 1997) |
| analytic therapy | Short term for psychoanalytic therapy. (05 Mar 2000) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |
| anticoagulant therapy | The use of anticoagulant drugs to reduce or prevent intravascular or intracardiac clotting. (05 Mar 2000) |
| antisense therapy | Use of antisense DNA for the inhibition of translation of a specific gene product for therapeutic purposes. (05 Mar 2000) |
| art therapy | The use of art as an adjunctive therapy in the treatment of neurological, mental, or behavioural disorders. (12 Dec 1998) |
| autoserum therapy | Therapy with serum obtained from the patient's own blood. (05 Mar 2000) |
| aversion therapy | <psychology> A form of behaviour therapy that pairs an unpleasant stimulus with undesirable behaviour(s) so that the patient learns to avoid the latter. See: aversive training. (05 Mar 2000) |
| aversive therapy | <psychology> A treatment that suppresses undesirable behaviour by simultaneously exposing the subject to unpleasant consequences. (12 Dec 1998) |
| behaviour therapy | The application of modern theories of learning and conditioning in the treatment of behaviour disorders. (12 Dec 1998) |
| biological therapy | <oncology> Treatment with substances that can stimulate the immune system to fight disease more effectively. Synonym: immunotherapy. (16 Dec 1997) |